Janus Henderson Group PLC Has $212,000 Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Janus Henderson Group PLC trimmed its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 68.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 17,800 shares of the company’s stock after selling 38,200 shares during the period. Janus Henderson Group PLC’s holdings in Olema Pharmaceuticals were worth $212,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Point72 Asset Management L.P. bought a new position in Olema Pharmaceuticals during the second quarter worth about $34,753,000. Great Point Partners LLC acquired a new position in shares of Olema Pharmaceuticals in the 2nd quarter worth approximately $8,622,000. Candriam S.C.A. lifted its position in shares of Olema Pharmaceuticals by 199.9% during the 2nd quarter. Candriam S.C.A. now owns 1,058,673 shares of the company’s stock worth $11,454,000 after buying an additional 705,655 shares during the period. Affinity Asset Advisors LLC acquired a new stake in Olema Pharmaceuticals in the 2nd quarter valued at $2,976,000. Finally, Charles Schwab Investment Management Inc. grew its position in Olema Pharmaceuticals by 168.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company’s stock valued at $3,949,000 after acquiring an additional 207,565 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Olema Pharmaceuticals Price Performance

OLMA stock opened at $6.75 on Monday. The business has a fifty day moving average price of $10.70 and a 200 day moving average price of $11.89. Olema Pharmaceuticals, Inc. has a fifty-two week low of $6.24 and a fifty-two week high of $16.77. The stock has a market capitalization of $386.76 million, a price-to-earnings ratio of -3.08 and a beta of 1.92.

Insider Activity

In related news, CEO Sean Bohen sold 52,328 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $9.37, for a total value of $490,313.36. Following the completion of the transaction, the chief executive officer now owns 298,836 shares in the company, valued at $2,800,093.32. The trade was a 14.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Cyrus Harmon sold 8,256 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $9.37, for a total value of $77,358.72. Following the completion of the transaction, the director now owns 772,277 shares in the company, valued at $7,236,235.49. The trade was a 1.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 73,036 shares of company stock worth $684,472. 19.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $27.00.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.